A drug used to treat HIV infection can “dramatically” slow the deadly spread of prostate cancer, new research has revealed. The study published online in the Cancer Research journal demonstrates that the antiretroviral drug maraviroc can substantially curb the lethal spread of prostate cancer in mice with the disease. Prostate cancer most commonly travels to the bones, leading to severe pain, disability and eventual death. But treatment with maraviroc reduced the spread, or metastasis, of prostate tumours to the bones, brain and other organs by 60 per cent in mice, the report explains.
One of the scientists, Dr Richard Pestell, from Thomas Jefferson University in Philadelphia, said the drug could move quickly through testing. “Because this work shows we can dramatically reduce metastasis in pre-clinical models and because the drug is already… approved for HIV treatment, we may be able to test soon whether this drug can block metastasis in patients with prostate cancer,” he said.